8-K: Quanterix Announces Preliminary Q3 2024 Results and Restatement of Prior Financials

Quanterix reported preliminary third-quarter results showing double-digit revenue growth but also announced a restatement of prior financial statements due to accounting errors.

Summary

• Quanterix has released preliminary financial results for the third quarter of 2024, showing a 13% increase in revenue to $35.7 million compared to $31.6 million in the same period last year.
• The company's GAAP gross margin was 58.9%, while non-GAAP gross margin was 53.4%.
• Net cash usage for the quarter was $3.3 million, and the company ended the quarter with $296.1 million in cash, cash equivalents, marketable securities, and restricted cash.
• Quanterix has identified errors in the capitalization of labor and overhead costs, which has led to a restatement of financial statements from 2021 through the first half of 2024.
• The restatement is expected to increase gross profit by $1.6 million in 2021, $0.4 million in 2022, and $2.1 million in 2023.
• The restatement is expected to decrease operating loss by $0.6 million in 2021 and $2.3 million in 2023, but increase it by $0.5 million in 2022.
• The company does not expect the errors to materially impact previously reported revenue or cash amounts.
• Quanterix has reaffirmed its full-year 2024 revenue guidance of $134 million to $138 million and expects its research-use only business to reach cash flow breakeven at revenues between $170 and $190 million.
• The company anticipates 2024 cash usage to be approximately $30 million.
• The company launched LucentAD Complete, a multi-marker test for Alzheimer's Disease, and released new ultra-sensitive 4-marker panels in neurology and immunology.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the restatement of financials and identified material weaknesses, despite positive revenue growth and product launches. The restatement and delay in filing the 10-Q are significant concerns.

Positives

• Quanterix achieved a 13% revenue increase in Q3 2024, marking the sixth consecutive quarter of double-digit growth.
• The company reaffirmed its full-year 2024 revenue guidance of $134 million to $138 million.
• Quanterix launched LucentAD Complete, a multi-marker test for Alzheimer's Disease, which offers improved amyloid classification.
• The company continues to advance its innovation rate with new product releases in neurology and immunology.
• The company has a strong cash position of $296.1 million.

Negatives

• Quanterix is restating its financial statements from 2021 through the first half of 2024 due to errors in the capitalization of labor and overhead costs.
• The company has identified a material weakness in its internal control over financial reporting related to inventory valuation.
• The restatement will result in adjustments to previously reported gross profit and operating loss figures.
• The company expects to delay the filing of its Q3 2024 10-Q report to complete the restatement.

Risks

• The company may have underestimated the scope and impact of the restatement.
• There are risks and uncertainties around the effectiveness of the company's internal control over financial reporting.
• The restated financial statements may take longer to complete than expected.
• The company's actual results may differ materially from forward-looking statements due to various risks and uncertainties.
• The restatement could negatively impact investor confidence and the company's stock price.

Future Outlook

Quanterix reaffirms its full-year 2024 revenue guidance of $134 million to $138 million and expects its research-use only business to reach cash flow breakeven at revenues between $170 and $190 million. The company anticipates 2024 cash usage to be approximately $30 million.

Management Comments

• Masoud Toloue, Chief Executive Officer of Quanterix, stated that the company continues to build on strong momentum, achieving its sixth consecutive quarter of double-digit growth.
• Masoud Toloue also noted that the company is pleased to reaffirm its full year 2024 outlook, especially given the muted growth in the tools space.

Industry Context

The announcement comes at a time when the tools space is experiencing muted growth, making Quanterix's double-digit growth particularly notable. The launch of the LucentAD Complete test positions the company well in the growing market for Alzheimer's diagnostics.

Comparison to Industry Standards

• Quanterix's 13% revenue growth in Q3 2024 is strong compared to the muted growth seen in the broader tools space, suggesting they are outperforming some competitors.
• The company's focus on ultra-sensitive biomarker detection and the launch of innovative products like LucentAD Complete are differentiating factors compared to companies relying on traditional methods.
• While specific competitor data is not provided, the company's emphasis on research and development and its partnerships with institutions like Mt. Sinai indicate a strong position in the biomarker detection market.
• The restatement of financials is a negative event, but the company's transparency and proactive approach to remediation are important for maintaining investor confidence.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the restatement of financial statements and the potential for a negative impact on the stock price.
• Employees may be affected by the company's efforts to remediate internal control weaknesses.
• Customers may benefit from the company's continued innovation and new product launches.
• Suppliers and creditors may be impacted by the company's financial performance and cash usage.

Next Steps

• The company intends to amend its Annual Report on Form 10-K for the year ended December 31, 2023.
• The company intends to amend its Quarterly Reports on Form 10-Q for the first and second quarters of 2024.
• The company intends to file its Quarterly Report on Form 10-Q for the third quarter of 2024 after the restatement is complete.
• The company will host a conference call on November 12, 2024, to discuss the results and restatement.

Key Dates

Keywords

Quanterix, financial results, restatement, revenue, gross margin, operating loss, Alzheimer's Disease, biomarkers, internal control, inventory valuation